Singular Genomics Systems, Inc. (NASDAQ:OMIC) Short Interest Down 17.6% in April

Singular Genomics Systems, Inc. (NASDAQ:OMIC) was the target of a significant decline in short interest in the month of April. As of April 15th, there was short interest totalling 603,300 shares, a decline of 17.6% from the March 31st total of 732,300 shares. Currently, 1.4% of the shares of the stock are short sold. Based on an average daily trading volume, of 113,500 shares, the short-interest ratio is presently 5.3 days.

Institutional Trading of Singular Genomics Systems

An institutional investor recently raised its position in Singular Genomics Systems stock. Weil Company Inc. grew its holdings in shares of Singular Genomics Systems, Inc. (NASDAQ:OMIC) by 16.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 138,202 shares of the company’s stock after acquiring an additional 20,000 shares during the quarter. Weil Company Inc. owned 0.19% of Singular Genomics Systems worth $64,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 65.80% of the company’s stock.

Singular Genomics Systems Price Performance

Shares of Singular Genomics Systems stock traded down $0.01 on Monday, reaching $0.40. 61,016 shares of the stock were exchanged, compared to its average volume of 113,703. The company has a debt-to-equity ratio of 0.05, a quick ratio of 9.77 and a current ratio of 10.51. The firm has a market cap of $29.45 million, a PE ratio of -0.31 and a beta of 1.39. The firm’s 50 day moving average is $0.50 and its 200-day moving average is $0.45. Singular Genomics Systems has a one year low of $0.31 and a one year high of $1.21.

Singular Genomics Systems (NASDAQ:OMIC) last released its earnings results on Monday, March 18th. The company reported ($0.34) earnings per share for the quarter. The business had revenue of $1.08 million for the quarter. Singular Genomics Systems had a negative return on equity of 45.33% and a negative net margin of 3,257.30%.

Analyst Ratings Changes

OMIC has been the topic of a number of recent research reports. UBS Group raised their price objective on Singular Genomics Systems from $0.40 to $0.50 and gave the stock a “neutral” rating in a research note on Wednesday, March 20th. The Goldman Sachs Group decreased their price target on Singular Genomics Systems from $0.95 to $0.85 and set a “neutral” rating on the stock in a research report on Monday, January 22nd.

About Singular Genomics Systems

Singular Genomics Systems, Inc, a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue.